non- tuberculous mycobacteria (ntms) and lung disease turkish thoracic society
DESCRIPTION
Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society 16 th Annual Conference. Philip Hopewell, MD Curry International Tuberculosis Center University of California, San Francisco. Non- tuberculous mycobacteria (NTMs). At least 140 species identified - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/1.jpg)
Non-tuberculous mycobacteria (NTMs) and lung disease
Turkish Thoracic Society
16th Annual Conference
Philip Hopewell, MDCurry International Tuberculosis CenterUniversity of California, San Francisco
![Page 2: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/2.jpg)
Non-tuberculous mycobacteria (NTMs)
At least 140 species identified Pathogenicity is highly variable Isolated from many environmental sources,
generally moist sites Can cause disease in almost any structure or tissue At least 40 reported as a cause of lung disease Distribution differs by geography Incidence/prevalence appears to be increasing Diagnosis of disease (vs. colonization) may be
difficult Response to treatment is slow and often incomplete
![Page 3: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/3.jpg)
NTMs and lung disease
Daley CL, Griffith DE. IJTLD 2010;14
frequent
more pathogenic1
2
2
2
3
MAC
> 7 days < 7 days
![Page 4: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/4.jpg)
NTMs gross appearance
![Page 5: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/5.jpg)
NTMs in Izmir
MAC 13 (42%) M. Szulgai 2 (6.5%)M. abcessus 5 (16%) M. Simiae 2 (6.5%) M. Kansasii 5 (16%) M. scrofulaceum 1 (3.2%)M. fortuitum 2 (6.5%) M. not speciated 1 (3.2%)
Isolates in 31 of 77 patients thought to be causative agents of lung disease.
![Page 6: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/6.jpg)
NTMs in Istanbul
Unidentified 43 (57%) M. fortuitum 3(8%)M. Abcessus 9 (28%) M. Szulgai 3 (8%)M. Avium complex 8 (25%) M. neonarum 1 (2%)M. Kansasii 5 (16%)M. Gordonae 6(16%) Total 75
![Page 7: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/7.jpg)
ATS/IDSA diagnostic criteria
Clinical (both required)
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CTscan with multifocal bronchiectasis and multiple small nodules and2. Appropriate exclusion of other diagnoses
Microbiological
1. Positive cultures from at least two sputum samples. or2. Positive culture result from at least one bronchial wash or lavage or
Griffith DE et al AJRCCM. 2007;175
![Page 8: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/8.jpg)
ATS/IDSA diagnostic criteria
Histological (+ microbiological)1. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or
2. Biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM
Griffith DE et al AJRCCM. 2007;175
![Page 9: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/9.jpg)
NTMs and lung disease: Risk factors
Structural defects• Bronchiectasis• COPD• Cystic fibrosis• Previous TB• Lady Windermere syndrome (?)
Impaired systemic immunity• Inherited deficiency• Acquired deficiency: HIV, immunosupressive
therapy
![Page 10: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/10.jpg)
MAC disease: Clinical patterns
• Bronchiectatic/cavitary disease• Middle lobe/lingular bronchiectasis (“Lady
Windermere syndrome”)• Disseminated MAC• Hypersensitivity pneumonitis (“hot tub lung”)
![Page 11: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/11.jpg)
M. avium disease and COPD
![Page 12: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/12.jpg)
M. avium; middle lobe/lingular bronchiectasis
![Page 13: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/13.jpg)
M. avium progression
18 months
![Page 14: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/14.jpg)
Disseminated MAC in HIV
![Page 15: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/15.jpg)
MAC in HIV: lymph node biopsy
![Page 16: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/16.jpg)
M. Avium hypersensitivity pneumonitis
Marras TK, et al. Chest. 2005; 127
![Page 17: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/17.jpg)
MAC hot tub lung: findings
Marras TK, et al. Chest. 2005; 127
![Page 18: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/18.jpg)
Treatment of MAC pulmonary disease Nodular/bronchiectatic (“mild”) disease:
• clarithromycin (1,000 mg) or azithromycin (500 mg),
• rifampin (600 mg), and
• ethambutol (25 mg/kg)
Fibrocavitary or severe nodular/bronchiectatic disease: • clarithromycin (500–1,000 mg) or azithromycin (250 mg), • rifampin (600 mg) or rifabutin (150–300 mg),• ethambutol (15 mg/kg) • consider three times-weekly amikacin or streptomycin early in therapy
• Patients should be treated until culture negative on therapy for 1 year.
Hypersensitivity• Macrolide and rifampin + corticosteroid (?)
three times weekly
daily
Griffith DE et al AJRCCM. 2007;175
![Page 19: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/19.jpg)
Treatment and prevention of disseminated MAC disease in HIV
Disseminated MAC disease• clarithromycin (1,000 mg/d) or azithromycin (250
mg/d) and ethambutol (15 mg/kg/d) with or without rifabutin (150–350 mg/d) daily.
Prophylaxis (AIDS with CD4 counts less than 50)
• Azithromycin 1,200 mg/week or clarithromycin 1,000 mg/day
• Rifabutin 300 mg/day (effective, less well tolerated)
Griffith DE et al AJRCCM. 2007;175
![Page 20: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/20.jpg)
MAC surgical treatment There are no established criteria for patient selection. There are potentially severe perioperative complications. There are few centers with extensive experience with
mycobacterial surgery. Surgical resection of limited (focal) disease in a patient
with adequate cardiopulmonary reserve to withstand partial or complete lung resection can be successful in combination with multidrug treatment regimens for treating MAC lung disease
Surgical resection of a solitary pulmonary nodule due to MAC is considered curative.
Mycobacterial lung disease surgery should be performed in centers with expertise in both medical and surgical management of mycobacterial diseases.
![Page 21: Non- tuberculous mycobacteria (NTMs) and lung disease Turkish Thoracic Society](https://reader035.vdocuments.us/reader035/viewer/2022081419/568148b8550346895db5d26e/html5/thumbnails/21.jpg)
San Francisco General HospitalSan Francisco General Hospital